StreetAlpha.app
Home › Stocks › CERT

Certara, Inc. (CERT)

Healthcare
$10.55
▼ −1.22%
LAST CLOSE · NOV 20

Certara sells biosimulation software, regulatory writing tools, and consulting services that help drug developers and regulators make decisions. It last closed at $10.55 on Nov 20, down 1.22% on the day. The next earnings report for CERT is expected around Thu, Feb 25, 2027. For the quarter ended Sep 2026, CERT reported EPS of $0.04 on revenue of $94.9M, with revenue up 4.4% from a year ago. Over its last 8 reports the stock moved an average of 11.2% the session after earnings.

AI Auto Pilots
Is CERT in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CERT.

Key Stats

Last 12 months
Results
Revenue
$425.8M
+13.3% vs a year ago
Net income
−$64.3M
−691.5% vs a year ago
EPS (diluted)
−$0.42
−700.0% vs a year ago
Free cash flow
$78.2M
18.4% margin
Valuation
Market cap
$1.6B
152.5M shares
P/E
–
No P/E while losing money
Price to sales
3.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$214.9M
At Sep 30
Debt
$291.2M
At Sep 30
Shareholder equity
$977.9M
Buybacks
$61.3M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $286.1M$286.1MFY2021FY2022: $335.6M$335.6MFY2022FY2023: $354.3M$354.3MFY2023FY2024: $385.1M$385.1MFY2024FY2025: $418.8M$418.8MFY2025

From CERT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Feb 25
Estimated date · Time not announced
Reported EPS
$0.04
Quarter ended Sep 2026
Year ago EPS
$0.01
+300.0% on a GAAP basis
Revenue
$94.9M
+4.4% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.04Dec '24Mar 2025: $0.03Mar '25Jun 2025: -$0.01Jun '25Sep 2025: $0.01Sep '25Dec 2025: -$0.04Dec '25Mar 2026: -$0.06Mar '26Jun 2026: -$0.36Jun '26Sep 2026: $0.04Sep '26Latest $0.04
Revenue by quarter
Dec 2024: $100.4MDec '24Mar 2025: $106.0MMar '25Jun 2025: $92.4MJun '25Sep 2025: $90.9MSep '25Dec 2025: $143.5MDec '25Mar 2026: $106.9MMar '26Jun 2026: $93.3MJun '26Sep 2026: $94.9MSep '26Latest $94.9M
How CERT moved after its last 8 reports
Average move the session after a report ±11.2%
Nov 5, 2026Time not announced+9.8%
Aug 4, 2026Time not announced−4.7%
May 11, 2026Time not announced−18.7%
Feb 26, 2026Time not announced+3.2%
Nov 6, 2025After the close−23.1%
Aug 6, 2025After the close+18.1%
Apr 14, 2025Time not announced+11.5%
Feb 26, 2025After the close+0.6%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on CERTStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on CERT
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on CERT

Technical Analysis

CERT · as of the Nov 20 close · updated each morning
Moving sideways

The stock sits between its 20 and 50 day averages. It is 29% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 46). The nearest support is the swing low (Nov 3) at $10.46, and the nearest resistance the Pivot at $10.61.

Short trendNeutral
Long trendBullish
MomentumFading
StretchNormal
VolatilityNormal, 5.5%/day
Key levels
$12.6152 week high+19.5%
$11.73Swing high (Oct 28)+11.2%
$11.3320 day average+7.4%
$10.80Pivot R1+2.4%
$10.61Pivot+0.6%
$10.55Last close
$10.46Swing low (Nov 3)−0.9%
$10.36Pivot S1−1.8%
$10.0350 day average−4.9%
$8.87100 day average−15.9%
$7.44200 day average−29.5%
$4.4552 week low−57.8%
Indicators
RSI (14)45.78Middle of its rangeNeutral
MACD0.28Below its signal lineBearish
Stochastic16.6Near the bottom of its rangeOversold
ADX (14)40.0Strong uptrend
Williams %R-94.1Oversold below −80, overbought above −20Oversold
CCI (20)-106.1Oversold below −100, overbought above 100Oversold
Rate of change−12.4%Change over 10 sessionsBearish
ATR (14)$0.58Typical daily range, 5.5% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for CERT

What happened before

See how CERT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow CERT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How CERT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for CERTHow many large options trades hit CERT, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

CERT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●134 buying vs 119 selling
  • ▲Held by funds +0.9 pts
  • ▲Funds holding +9
  • ▼Superinvestors: 0 added, 4 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding252243+3.7%
In funds' top 1024−50.0%
Held by funds89.4%88.5%+0.9 pts
New / increased51 / 8356 / 89−7.6%
Reduced / sold out77 / 4270 / 70−15.0%
Put/call ratio–0.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CERT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

CERT Insider Trading

All filings →
Insider trading · 12 months
No open market trades in 12 months
Bought$00 buys · 0 insiders
Sold$00 sales · 0 insiders
DecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 11, 2025William F FeeheryCEOBuy24,096$8.30$200K
Sep 9, 2025Leif E PedersenPresident, Chief Commercal OffSale plan51,224$10.92$559K
Every insider buy and sale for CERT over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See CERT insider trades →

From SEC Form 4 filings by CERT's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CERT is in one of them and how their past CERT trades turned out.

CERT in the AI portfolios
Loading…

CERT News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CERT in an article yet. Here's the latest on the wider market.

CERT in the news

About Certara

Certara is based in Radnor, Pennsylvania, and provides biosimulation software, regulatory science tools, and consulting services for drug development. Its products include the Simcyp Simulator, which predicts how drugs behave in the body, and the Phoenix software for analyzing pharmacokinetic data. The company also offers CoAuthor software and related services to help draft regulatory submissions. Its customers include biopharmaceutical and biotech companies, academic institutions, and drug regulatory agencies.

Headquarters
Radnor, PA